Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Kyle Teamey joins RA Capital as a Managing Partner, Planetary Health. Rye Lane to Peter Pan & Wendy: the seven best films to watch on TV this Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Peter Pan & Wendy supports the theory that Peter Pan is the real villain of his respective franchise with its depiction of the beloved Disney character. Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Steve's survey is fascinating. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Mario held a Project Director position at BARDA working on Universal Flu Vaccine and leading the technical selection and completion of multiyear/multi million vaccine development programs. After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Soumya completed his postdoc at Brigham and Womens Hospital and held an Assistant Professor of Neuroscience role at Harvard Medical School Neurology Department where he contributed to the Harvard Neurodiscovery Centers (HNDC) academic drug discovery initiative as a modeler and drug hunter. Chris Caliri is the Chief Information Officer at RA Capital Management. Shannon is a Receptionist and Facilities Administrator at RA Capital Management. During his four years with Sage, he helped lead the growth of the organization through multiple capital raises, the launch of the companys first product, and execution of a transformational, multi-billion collaboration. Nothing contained on the website constitutes investment advice, and the views expressed should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. Angela previously held roles as Senior Director of Clinical Operations and Patient Advocacy at Vigil Neuroscience and at Ra Pharmaceuticals. Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. Cristina has nearly a decade of experience in the biotech and life sciences industries. Matt comes to RA from Localytics where he served as a Senior Software Engineer for the past two years. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). Tom has a BS in Physiological Sciences from University of California Los Angeles. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Her graduate research investigated novel small molecule approaches to treating vestibular schwannoma and neurofibromatosis type 2. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and reasonably well-trained dog. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Peter conducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Michael holds a B.S. He continues advising both in a consultant capacity. Prior to Biogen, Mike worked at Bain & Company as a consultant specializing in healthcare. As a founder and member of Constellations executive team Patrick materially contributed to several successful financing rounds and deals, including a crossover round, an IPO and the ultimate acqusition of the company. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Ben holds a BS in Biology and an MS in Virology from the University of Nebraska, Lincoln, and a PhD in Cancer Biology from the Tufts University School of Medicine. Assistant General Counsel (RA Capital), RAVen Counsel. Kolchinsky is a founder and Managing Partner of RA Capital Management, L.P., a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, and diagnostics, where he has worked since 2001. Kaleen Sullivan is a Research Operations Manager at RA Capital Management. Angela has a BA in Pre-Medicine and French Studies from the University of Minnesota. In 2013 was awarded a Medical Research Council Clinical Scientist Fellowship. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. Copyright 2023 Surperformance. Peter Kolchinsky founded 5 companies, among them: Research Alliance Corp. II, Therapeutics Acquisition Corp. and RA Capital Management LP (Private Equity). Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Prior to joining RA Capital, Jeff worked for over 10 years as an institutional equity sales trader, primarily at KCG Holdings, Inc., where he managed the Boston office. Kathryn's primary responsibilities at RA Capital are to coordinate calendars, events, and company meetings for the TechAtlas division. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley Kathryn Spencer is an Executive Assistant at RA Capital Management. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Lorena Chen is a Fund Controller at RA Capital Management. David Migl is an Analyst on the Investment Team at RA Capital Management. He also provided additional system administration and training for the desktop engineering team. He holds a Bachelors degree in Electronics and Communications from Anna University, and a Masters degree in Computer Science from Northeastern University. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Emily Gransky is VP of Recruiting at RA Ventures (RAVen). EMEA +44 20 7330 7500. He earned his MS in Bioinformatics from Boston University. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Anthonys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. View Profile. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Prior to RA, Ryan was at KPMG where he was a Senior Associate. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. Let's Throw a Patent-Burning Party | by Peter Kolchinsky - Medium Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Ben has also mapped competitive landscapes with a focus on cardiovascular diseases and regenerative medicine as a member of the Cardio-Renal Team within the TechAtlas division of RA Capital. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). The Great American Drug Deal examines the healthcare landscape through the lens of this contract, including the government's role in inventing drugs, direct-to-consumer advertising, the opioid crisis, the price-jacking of old drugs, and the impact on America of lower drug costs in other countries. Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. Eric is the Chief Compliance Officer at RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. He worked previously as a Patient Coordinator at Massachusetts General Hospital. Biotech's Dulcius Ex Asperis: The Way Through This Downturn Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. (L-R) Robert Morgan, Jamie Anderson and Mark Blutman, collaborators on forthcoming 'Arigato Tokyo' Courtesy/Getty. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. After the acquisition, Tim was named President of Genzymes Renal Division and GelTex Pharmaceuticals. He also gained extensive legislative and public policy experience early in his career as a Legislative Aide to former United States Senator David Boren, and as a Domestic Policy Advisor to former Vice President Al Gore. Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. Sris primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Michael Calore is the Director of Investor Relations at RA Capital Management. RA Capital | Team Tim received his A.B. Prior to that, he was a Life Sciences Investment Associate at Brigham Capital. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Meredith is a Senior Research Assistant at RA Capital Management. Erin Clutter is the Head of Graphics at RA Capital Management. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post Jeff holds a BA in Economics and Psychology from Georgetown. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Amber is Special Projects Operations Manager/Chief of Staff at RA Capital Management. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Our website uses cookies to distinguish you from other users of our website. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Jeff Breay is a Head Trader at RA Capital Management. Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn Peter Kolchinsky He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. She previously worked as a Finance Associate at the MFA Companies. and Ultragenyx Pharmaceuticals. Benjamin previously worked in clinical research as a Site Operations Associate for a contracted research organization specializing in Ophthalmology. 239 Kelton St, Allston, MA . In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Prithviraj works on both public and private investments with a focus on Healthcare, Technology, and Services. Garrett received a BS with honors from the California Institute of Technology while publishing his first paper with Dr. Paul H. Patterson, holds a PhD in Immunology from Stanford University, where he studied hematopoietic stem and progenitor cells with Dr. Irving L. Weissman, and completed his post-doctoral training at Childrens Hospital Boston/Harvard Medical School studying ES/iPSC specification to the hematopoietic fate with Dr. George Q. Daley. What is Peter Kolchinsky Net Worth? Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and PETER KOLCHINSKY, PhD Managing Partner RAJEEV SHAH Managing Partner ANDREW LEVIN, MD/PhD Partner and Managing Director JOSH RESNICK, MD Senior Managing Director PETER BALOGH Analyst GUNES BOZKURT, PhD Analyst TESS CAMERON Principal NATE DAVIS Analyst DEREK DiROCCO, PhD Partner CRISTINA GHENOIU, PhD Principal MICHAEL GILLESPIE, MD Analyst Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Brigid holds a BS in Chemistry (Hons) from the Commonwealth Honors College at the University of Massachusetts, Amherst (2002) and a PhD in Materials Science and Engineering from Johns Hopkins University (2009). Michael Sherman is a Venture Partner at RA Ventures. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners within RAVen. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. Walter has a BS in Biology from Davidson College and a MS in Genetics from University of Georgia. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Michael held leadership positions at Citigroup Hedge Fund Services in both Fund Accounting and Product Management before joining Centerbridge. Directed by David Lowery ("The Green Knight") and featuring Law as Captain Hook, the live-action remake leans into the bittersweet coming-of-age theme of J.M. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Previously, Neil was Director, Business Development and Project Management at CiVentiChem (acquired by Sterling Pharma Solutions). Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). Sarah Reed is the General Counsel at RA Capital Management. Kate previously served as Health Law Assistant at Mintz. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. From time to time we may post specific open positions, but more often we will create positions for the right people. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Sarah teaches a course at Harvard Law School on venture capital fund formation. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. Brendan has more than 18 years of experience as a tax professional. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. Her primary responsibilities are to assist with all finance operations related to the Firm. Peter also leads the firms engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients, physicians, researchers, policymakers, and industry. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Vikram trained in clinical pathology at the Brigham and Womens Hospital where he was chief resident. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Jacqueline is an Associate, Strategic Finance at RA Capital Management. Barrie's 1911 novel. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. James is admitted to practice law in the Commonwealth of Massachusetts. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. He received his doctorate in Organic Chemistry from Ohio University, and was a Fellow and Instructor in Department of Medicine, Boston University School of Medicine. 1 reply 0 retweets 13 likes Priscilla has a B.S. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Anurag Kondapalli is a Principal on the Investment Team at RA Capital Management. Pathways to | Harvard Office of Technology Development Mario is a Venture Partner and Head of Vaccines at RA Capital. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Peter Kolchinsky, Ph.D. is a biotechnology investor and a scientist. Ben Dake is a Venture Associate at RA Capital Management. Henry has a BA in Biology & Economics from Dartmouth College. Americas +1 212 318 2000. Prior to Flagship, Emily held roles as Associate Director, Head of Global Talent Acquisition and Associate Director, Recruiting Operations & Analytics at bluebird bio.
Two Views Of The River Quizlet,
What Does A Flamingo Mean Sexually,
Steve Smith Motorcycle Accident,
Articles P
